pharmaphorum| News & views on pharma and biotech’s evolving future

Digital

Sponsored

Solution Spotlight: InsightBrain – AI-powered precision inte...

InsightBrain gives commercial leaders the signals and direction to deliver stronger launches, defend share, and stay ahead of the competition.

News

Novartis CEO joins board of "responsible" AI firm Anthropic

In another signal of the deepening relationship between the pharma and AI sectors, Novartis CEO Vas Narasimhan has joined the board of Anthropic.

R&D

Building a scalable GLP-1 care model

News

Scientists issue call to arms over antifungal resistance

Infectious disease experts from around the world are calling for concerted action to combat a "silent surge" in resistance to antifungal drugs.

R&D

Parkinson's disease affected hands on an elderly man

Parkinson’s disease: Transitioning from symptom control to d...

The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.

Featured Content

R&D

Parkinson’s disease: Transitioning from symptom control to d...

The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.

R&D

Building a scalable GLP-1 care model

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Patients

pharmaphorum podcast Episode 254, Thomas Goetz, Drug Story

Every drug is a story, with Thomas Goetz

Thomas Goetz, creator and host of the Drug Story podcast on recognising pharmaceutical medicine as the socially and morally complex market that it is.

R&D

LSX2026: Non-opioid pain relief and pharma positivity, with ...

Mike Cooke, CEO of AmacaThera, spoke with pharmaphorum at the LSX World Congress, including about non-opioid pain relief.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Newsletters and Deep Dive
digital magazine

Latest News

News

Novartis CEO joins board of "responsible" AI firm Anthropic

In another signal of the deepening relationship between the pharma and AI sectors, Novartis CEO Vas Narasimhan has joined the board of Anthropic.

News

Scientists issue call to arms over antifungal resistance

Infectious disease experts from around the world are calling for concerted action to combat a "silent surge" in resistance to antifungal drugs.

News

Daiichi exits OTC, with $1.55bn unit sale to Suntory

Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.

News

Parkinson's charity partners Biognosys on biomarker project

A new R&D project will try to develop assays for LRRK2, a biomarker linked to Parkinson's that has emerged as a major drug target in the disease.

Views & Analysis

R&D

Parkinson’s disease: Transitioning from symptom control to d...

The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.

Patients

Anatomical graphic concept of a liver in 3D

Rewriting the MASLD playbook

Effective care now requires identifying metabolic risks early and addressing the broader factors driving liver damage.

Digital

Sponsored

Solution Spotlight: InsightBrain – AI-powered precision inte...

InsightBrain gives commercial leaders the signals and direction to deliver stronger launches, defend share, and stay ahead of the competition.

Patients

Every drug is a story, with Thomas Goetz

Thomas Goetz, creator and host of the Drug Story podcast on recognising pharmaceutical medicine as the socially and morally complex market that it is.